Last Updated: October 11, 2026

Patent: 10,822,630

✉ Email this page to a colleague

Summary for Patent: 10,822,630

Title:	Process for manipulating the level of glycan content of a glycoprotein
Abstract:	The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
Inventor(s):	Daniel R. Leiske, Michael T. Trentalange
Assignee:	Amgen Inc
Application Number:	US16/783,117
Patent Claims:	see list of patent claims

Details for Patent 10,822,630

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 1, 2010	⤷ Start Trial	2040-02-05
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	⤷ Start Trial	2040-02-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,822,630

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	201703729	⤷ Start Trial
South Africa	202006002	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2016089919	⤷ Start Trial
United States of America	10167492	⤷ Start Trial
United States of America	2017362625	⤷ Start Trial
United States of America	2019085370	⤷ Start Trial
United States of America	2020172947	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.